Fizazi, et al. ARAMIS: Efficacy and safety of darolutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC). ASCO-GU 2019, abstract 140.
Grote variatie in voorschrijven hormoontherapie naast radiotherapie
dec 2020 | Radiotherapie, Uro-oncologie